Management of Cutaneous Lupus Erythematosus with JAK Inhibitor Therapy: An Evidence-Based Review
Cutaneous lupus erythematosus (CLE) is a rare, isolated form of lupus erythematosus localized to the skin. CLE results in a wide variety of dermatologic manifestations. With no FDA-approved treatments for CLE, initial treatment typically involves topical and systemic corticosteroids. The use of Janus kinase inhibitors (JAKi) for CLE remains novel. This systematic review examines the literature and summarizes the effectiveness and safety outcomes of JAKi therapies in treating CLE.